Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on June 6, 2025
Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
GlobeNewswire
·
June 6, 2025
Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate (PPi) efflux via on-target engagement of the ABCC6 …
Polpharma Group soutient l’action urgente de l’UE visant à garantir l’accès aux médicaments et à renforcer la souveraineté pharmaceutique européenne
GlobeNewswire
·
June 6, 2025
AMSTERDAM, 06 juin 2025 (GLOBE NEWSWIRE) -- Polpharma Group, fabricant européen de produits pharmaceutiques de premier plan, s’est joint aux autres membres de l’association Medicines for Europe pour signer une lettre ouverte adressée aux Premiers ministres …
Burning Rock Reports First Quarter 2025 Financial Results
GlobeNewswire
·
June 6, 2025
GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today …
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
GlobeNewswire
·
June 6, 2025
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. …
浩鼎自创ADC平台GlycOBI® 首宗技术合作案 携手美国TegMine开发ADC
GlobeNewswire
·
June 6, 2025
台湾, June 06, 2025 (GLOBE NEWSWIRE) -- 浩鼎生技（以下简称「浩鼎」）（4174.TWO）今（06/06）宣布，与美国TegMine Therapeutics, Inc.（以下简称「TegMine」）签署ADC研发服务合约（Master Services Agreement, MSA）；TegMine 是一家总部位于美国旧金山的生物制药公司，专注于开发针对癌症相关糖蛋白的创新抗体疗法。浩鼎则致力于开发抗癌新药及聚焦研发次世代抗体药物复合体（ADCs）。 根据合约，浩鼎将与 …
浩鼎自創ADC平台GlycOBI® 首宗技術合作案 攜手美國TegMine開發ADC
GlobeNewswire
·
June 6, 2025
台灣, June 06, 2025 (GLOBE NEWSWIRE) -- 浩鼎生技（以下簡稱「浩鼎」）（4174.TWO）今（06/06）宣布，與美國TegMine Therapeutics, Inc.（以下簡稱「TegMine」）簽署ADC研發服務合約（Master Services Agreement, MSA）；TegMine 是一家總部位於美國舊金山的生物製藥公司，專注於開發針對癌症相關醣蛋白的創新抗體療法。浩鼎則致力於開發抗癌新藥及聚焦研發次世代抗體藥物複合體（ADCs）。 根據合約，浩鼎將與 …
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
GlobeNewswire
·
June 6, 2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for …